Icon Wealth Advisors LLC Has $2.10 Million Stock Holdings in Zoetis Inc. $ZTS

Icon Wealth Advisors LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 32.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 16,602 shares of the company’s stock after selling 7,801 shares during the period. Icon Wealth Advisors LLC’s holdings in Zoetis were worth $2,095,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Nordea Investment Management AB boosted its position in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after buying an additional 2,179,578 shares in the last quarter. Seilern Investment Management Ltd boosted its position in Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after buying an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after buying an additional 935,432 shares in the last quarter. Pincus Capital Management LP acquired a new stake in Zoetis in the fourth quarter valued at approximately $2,109,000. Finally, Prudential PLC boosted its position in Zoetis by 17.7% in the third quarter. Prudential PLC now owns 197,852 shares of the company’s stock valued at $28,950,000 after buying an additional 29,702 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on ZTS shares. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Citigroup cut their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Finally, UBS Group dropped their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $133.92.

Zoetis Price Performance

ZTS stock opened at $79.51 on Friday. The company has a fifty day moving average price of $96.94 and a 200-day moving average price of $114.22. The company has a market capitalization of $33.33 billion, a P/E ratio of 13.19, a PEG ratio of 1.24 and a beta of 0.75. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $167.38. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

Insider Activity at Zoetis

In other news, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 11,650 shares of company stock worth $886,384 over the last quarter. Company insiders own 0.22% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
• Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
• Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. (NYSE: ZTS) until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.